Corrigendum to "Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy" [<i>Kidney International Reports</i> Volume 6, Issue 4, April 2021, Pages 1183-1188].
對於「Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy」的更正 [<i>Kidney International Reports</i> 第6卷,第4期,2021年4月,頁1183-1188]。
Kidney Int Rep 2024-07-31
Corrigendum to "WCN24-1897 MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE AND MONOCLONAL IMMUNOGLOBULIN RELATED KIDNEY DAMAGE IN B-CELL MALIGNANCIES: THE REAL CLINICAL PRACTICE" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S624-S625].
對於「WCN24-1897 MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE AND MONOCLONAL IMMUNOGLOBULIN RELATED KIDNEY DAMAGE IN B-CELL MALIGNANCIES: THE REAL CLINICAL PRACTICE」的更正 [<i>Kidney International Reports</i> 第9卷,第4期,補充,2024年4月,頁S624-S625]。
Kidney Int Rep 2024-07-31
Corrigendum to "WCN24-1051 CLINICAL PROFILE, DIAGNOSIS, THERAPEUTIC INTERVENTION AND COMPLICATIONS IN RENAL BIOPSY IN CKD POPULATION - SINGLE CENTER 20 YEARS' EXPERIENCE" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S86].
對於「WCN24-1051 CLINICAL PROFILE, DIAGNOSIS, THERAPEUTIC INTERVENTION AND COMPLICATIONS IN RENAL BIOPSY IN CKD POPULATION - SINGLE CENTER 20 YEARS' EXPERIENCE」的更正 [<i>Kidney International Reports</i> 第9卷,第4期,補充,2024年4月,第S86頁]。
Kidney Int Rep 2024-07-31
Corrigendum to "The Association Between Metabolic Syndrome, Hyperfiltration, and Long-Term GFR Decline in the General Population" [<i>Kidney International Reports</i> Volume 8, Issue 9, September 2023, Pages 1831-1840].
對於「代謝症候群、高過濾率與一般人群長期GFR下降之間的關聯」的更正 [<i>Kidney International Reports</i> 第8卷,第9期,2023年9月,頁1831-1840]。
Kidney Int Rep 2024-07-31
Corrigendum to "Nitric Oxide Precursors and Dimethylarginines as Risk Markers for Accelerated Measured GFR Decline in the General Population" [<i>Kidney International Reports</i> Volume 8, Issue 4, April 2023, Pages 818-826].
對於「Nitric Oxide Precursors and Dimethylarginines as Risk Markers for Accelerated Measured GFR Decline in the General Population」的更正 [<i>Kidney International Reports</i> 第8卷,第4期,2023年4月,頁818-826]。
Kidney Int Rep 2024-07-31
Corrigendum to "WCN24-658 Comparative Analysis of Zwitterionic Materials and Polyvinyl Pyrrolidone for Enhancing Dialysis Membrane Hemocompatibility and Psychological Symptoms in Patients" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Pages S362-S363].
對於「WCN24-658 比較分析 Zwitterionic 材料和聚乙烯吡咯烷酮以增強透析膜的血液相容性及患者的心理症狀」的更正 [<i>Kidney International Reports</i> 第9卷,第4期,補充,2024年4月,頁S362-S363]。
Kidney Int Rep 2024-08-19
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容,或是有其他相關的問題,請提供更多細節!
PubMedDOI
Corrigendum to "WCN24-660 Comparative Analysis of High Flux and Low Flux Dialysis Membranes: In-Situ Synchrotron Imaging and Experimental Ex-Vivo Studies" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S363].
對於「WCN24-660 高通量與低通量透析膜的比較分析:原位同步輻射成像及實驗性體外研究」的更正 [<i>Kidney International Reports</i> 第9卷,第4期,補充,2024年4月,第S363頁]。
Kidney Int Rep 2024-08-19
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容,或是有其他相關的問題,請提供更多細節!
PubMedDOI
Corrigendum to "WCN24-786 PHASE I DOSE ESCALATION STUDY OF SHR6508, A CALCIUM-SENSING RECEPTOR AGONIST, IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Pages S368-S369].
對於「WCN24-786 PHASE I DOSE ESCALATION STUDY OF SHR6508, A CALCIUM-SENSING RECEPTOR AGONIST, IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM」的更正 [<i>Kidney International Reports</i> 第9卷,第4期,補充,2024年4月,頁S368-S369]。
Kidney Int Rep 2024-08-19
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容,或是其他相關的問題,請提供更多細節!
PubMedDOI
Corrigendum to "WCN24-2499 CAVEOLIN-1 AND CAVEOLIN-2 AS POTENTIAL URINARY EARLY BIOMARKERS OF RENAL INJURY IN ACUTE CHOLESTASIS IN RATS" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S541].
對於「WCN24-2499 CAVEOLIN-1 和 CAVEOLIN-2 作為急性膽汁淤積大鼠腎損傷的潛在尿液早期生物標記」的更正 [<i>Kidney International Reports</i> 第9卷,第4期,補充,2024年4月,第S541頁]。
Kidney Int Rep 2024-08-19
Corrigendum to "WCN24-813 MANAGEMENT OF ACUTE FLUID OVERLOAD IN HEART FAILURE PATIENTS WITH CKD USING HOME DELIVERED SUBCUTANEOUS FUROSEMIDE" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S251-S252].
對於「WCN24-813 心衰竭合併慢性腎病患者急性液體過載的管理:使用居家配送的皮下注射 Furosemide」的更正 [<i>Kidney International Reports</i> 第9卷,第4期,補充,2024年4月,頁S251-S252]。
Kidney Int Rep 2024-09-18
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容,或是其他相關的問題,請提供更多細節!
PubMedDOI